GEN Exclusives

More »

GEN News Highlights

More »
Oct 27, 2006

Argos Awarded $21M to Develop its Personalized HIV Therapy

  • Argos Therapeutics has been awarded a five-year, $21-million NIH contract to develop HIV immunotherapy candidates. Argos is developing personalized, RNA-loaded dendritic cell immunotherapy products designed to train the patient’s immune system to recognize, target, and destroy unique features of their disease.

    The goal of the contract, issued by the NIAID, is to determine the immunogenicity of Argos’ HIV immunotherapy candidate currently in clinical trials and subsequently develop more potent product candidates.

    Argos has partnered with a number of leading institutions which will participate in the development program. The award will cover substantially all costs associated with the development of such HIV immunotherapies, as well as portions of costs related to Argos’ current HIV candidate development. 



GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »